Pyramidal Weakness: Clinical Characteristics and Associated Findings

Core Clinical Features and Pathophysiology

• The American Association of Neurology notes that pyramidal weakness is associated with upper motor neuron signs, including hypertonia, hyperreflexia, and positive Babinski sign, in patients with hepatic encephalopathy 1, 2
• The European Academy of Neurology reports that somatotopic organization within the internal capsule means that lesions in the anterior portion of the posterior limb predominantly affect upper limb fibers, while posterior lesions affect lower limb fibers, producing "disproportionate hemiparesis" 3

Clinical Context and Associated Findings

• The American College of Gastroenterology states that hepatic myelopathy presents with progressive spasticity and weakness of lower limbs with hyperreflexia, representing severe motor abnormalities exceeding mental dysfunction 1, 2
• The American College of Radiology notes that neurodegeneration with brain iron accumulation (NBIA) classically presents with gait disturbances, dystonia, dysarthria, spasticity, and pyramidal tract signs 4
• The American Academy of Neurology reports that motor neuron diseases like ALS present with hypertonicity and hyperreflexia (upper motor neuron signs) combined with fasciculations, weakness, and atrophy (lower motor neuron signs) 4

Important Clinical Distinctions

• The European Academy of Neurology advises that pyramidal weakness must be distinguished from extrapyramidal dysfunction (hypomimia, rigidity, bradykinesia, parkinsonian tremor), which represents a different motor system and should not be confused with pyramidal signs 1, 2
• The American College of Physicians states that areflexia (as seen in Miller-Fisher syndrome or Guillain-Barré syndrome) indicates peripheral nerve or lower motor neuron pathology, not pyramidal tract involvement 5, 6

Síndrome Piramidal Proporcionado Completo

Evidencia Clínica

• La arreflexia, como en síndrome de Guillain-Barré o Miller-Fisher, indica patología de nervio periférico o neurona motora inferior, no compromiso del tracto piramidal, según Nature Reviews Neurology 7

Contexto Clínico

• En esclerosis lateral amiotrófica (ELA), los signos piramidales son esenciales para el diagnóstico, aunque no siempre están presentes al inicio, y aproximadamente 26% de pacientes con ELA no muestran signos piramidales en la primera visita [@2@]
• Aproximadamente 11.5% presentan síndrome piramidal completo inicialmente en esclerosis lateral amiotrófica (ELA) [@3@]
• El tiempo medio de aparición de los primeros signos piramidales en pacientes sin signos iniciales es de 4.5 meses en esclerosis lateral amiotrófica (ELA) [@4@]